US 11,926,673 B2
Antagonistic CD40 monoclonal antibodies and uses thereof
Aaron Yamniuk, Vancouver (CA); Mary Struthers, Edison, NJ (US); Stanley R. Krystek, Jr., Ringoes, NJ (US); Akbar Nayeem, Newtown, PA (US); and Ginger Rakestraw, Somerville, MA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Jan. 19, 2022, as Appl. No. 17/579,468.
Application 17/579,468 is a continuation of application No. 17/080,626, filed on Oct. 26, 2020, granted, now 11,254,750.
Application 17/080,626 is a continuation of application No. 16/686,596, filed on Nov. 18, 2019, granted, now 11,261,258.
Claims priority of provisional application 62/769,514, filed on Nov. 19, 2018.
Prior Publication US 2022/0144962 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 37/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 47/68 (2017.08); A61K 47/6849 (2017.08); A61P 37/00 (2018.01); C07K 16/468 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); C07K 14/70578 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
 
1. A pharmaceutical composition comprising:
a) an antibody, or antigen binding portion thereof that specifically binds to human CD40, and
b) a pharmaceutically acceptable carrier,
wherein the antibody or antigen binding portion thereof comprises a first polypeptide portion comprising a heavy chain variable region and a human heavy chain constant region, and a second polypeptide portion comprising a light chain variable region and a human light chain constant region, wherein:
said heavy chain variable region comprises a CDR1 comprising SEQ ID NO: 1, a CDR2 comprising SEQ ID NO: 2, and a CDR3 comprising SEQ ID NO: 3; and
said light chain variable region comprises a CDR1 comprising SEQ ID NO: 7, a CDR2 comprising SEQ ID NO: 8, and a CDR3 comprising SEQ ID NO: 9.